IGN523   Click here for help

GtoPdb Ligand ID: 8737

Compound class: Antibody
Comment: IGN523 is a humanized anti-CD98 (SLC3A2) monoclonal antibody being investigated as a potential therapy for acute myeloid leukemia (AML) [1-2].
Click here for help
No information available.
Summary of Clinical Use Click here for help
A single Phase 1 clinical trial (NCT02040506) is assessing IGN523 in patients with relapsed or refractory AML.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
CD98 (SLC3A2) forms a functional amino acid transporter in association with the L-type amino acid transporter 1 (LAT1, SLC7A5). Amino acid transport in to these cells is essential for cell survival. Approximately 90% of AML cells express high levels of CD98 making this proetin a promising target for AML treatment. Antibody blocking of CD98 function directs the cells towards the apoptotic pathway and makes them vulnerable to natural killer cell destruction [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02040506 A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML Phase 1 Interventional Igenica Biotherapeutics, Inc.